Table 1.
FDA approved combination chemotherapy.
| Drug 1 | Drug 2 | Type of Cancer | Date |
|---|---|---|---|
| Lenvatinib capsule (cytotoxic) | Everolimus (cytotoxic) | Advanced renal cell carcinoma | May 2016 |
| Obinutuzumab (Biologic) | Bendamustine (cytotoxic) | Follicular Lymphoma After use of obinutuzumab monotherapy | February 2016 |
| Palbociclib (cytotoxic) | Fulvestrant (Cytotoxic) | HR+, HER2-advanced or metastatic breast cancer | February 2016 |
| Elotuzumab (Biologic) | Lenalidomide, and Dexamethasone (Cytotoxic) | Multiple melanoma | November 2015 |
| Necitumumab (Biologic) | Gemcitabine, and cisplatin (Cytotoxic) | Metastatic squamous non-small cell lung cancer | November 2015 |
| Trametinib (Cytotoxic) | Dabrafenib (Cytotoxic) | Unresectable or metastatic melanoma with BRAF V600E or V600K mutations | November 2015 |
| Ixazomib (Cytotoxic) | Lenalidomide and Dexamethasone (Cytotoxic) | Multiple myeloma | November 2015 |
| Irinotecan liposome (Cytotoxic) | Fluorocil and Leucovorin (Cytotoxic) | Metastatic adenocarcinoma of pancreas | October 2015 |
| Nivolumab (Biologic) | Ipilimumab (Biologic) | BRAF V600 wild-type, unresectable or metastatic melanoma | September 2015 |
| Carfilzomib (Cytotoxic) | Lenalidomide and Dexamethasone (Cytotoxic) | Relapsed multiple myeloma | July 2015 |
| Ramucirumab (Biologics) | FOLFIRI (Cytotoxic) | Metastatic colorectal cancer | April 2015 |
| Dinutuximab (Biologics) | Garnulocyte-macrophage colony stimulating factor, interleukin-2, 13 cis-retinoic acid (Biologic) | Neuroblastoma in pediatric patients | March 2015 |
| Panobinostat (Cytotoxic) | Bortezomib and Dexamethasone (Cytotoxic) | Multiple myeloma | February 2015 |
| Palbociclib (Cytotoxic) | Letrozole (Cytotoxic) | Postmenopausal women with ER+HER2-advanced breast cancer. | February 2015 |
| Ramucirumab (Biologic) | Docetaxel (Cytotoxic) | Non-small cell lung cancer. | December 2014 |
| Bevacizumab solution (Biologic) | Paclitaxel, or Topotecan (Cytotoxic) | Platinum resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. | November 2014 |
| Ramucirumab (Biologic) | Paclitaxel (Cytotoxic) | Advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma | November 2014 |
| Idelalisib (Cytotoxic) | Rituximab (Biologic) | Relapsed Chronic Lymphocytic Leukemia (CLL) | July 2014 |
| Ofatumumab (Biologic) | Chlorambucil (Cytotoxic) | Previously untreated patients with CLL | April 2014 |
| Trametinib (Cytotoxic) | Dafrafenib (Cytotoxic) | Metastatic Melanoma with a BRAF V600E or V600K mutation | January 2014 |
| Obinutuzumab (Biologic) | Chlorambucil (Cytotoxic) | Previously untreated CLL | November 2013 |
| Pertuzumab (Biologic) | Trastuzumab (Biologic) / Docetaxel (Cytotoxic) | Neoadjuvant treatment of patients with HER2-positive breast cancer. | September 2013 |
| Abraxane (Cytotoxic) | Gemcitabine (Cytotoxic) | Metastatic adenocarcinoma of the pancreas. | September 2013 |
| Bevacizumab (Biologic) | fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin (Cytotoxic) | Metastatic colorectal cancer (mCRC) | January 2013 |